Vinay Prasad

uturn
Biotech

uniQure's gene therapy for Huntington's hits FDA roadblock

UniQure said the FDA backtracked on their agreement by deeming the phase 1/2 data based on an external control inadequate to support an application.
Angus Liu Nov 3, 2025 10:03am
Dark and dramatic sky with sunlight

After 'complete standstill,' biotech market reaches new normal

Aug 20, 2025 11:04am
clock delay wait time alarm

Regenxbio's Hunter gene therapy latest to face FDA delay

Aug 19, 2025 10:30am
FDA
Favicon Fierce Pharma

Vinay Prasad is back at the FDA after last month's surprise ouster

Aug 9, 2025 12:22pm
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Prasad exit signals more permissive FDA for cell and gene field

Jul 31, 2025 9:10am
FDA
Favicon Fierce Pharma

Vinay Prasad departs FDA amid controversy over gene therapy

Jul 30, 2025 9:33am